Skip to main content

Priftin Side Effects

Generic name: rifapentine

Medically reviewed by Last updated on Jan 23, 2023.

Note: This document contains side effect information about rifapentine. Some dosage forms listed on this page may not apply to the brand name Priftin.


More frequent side effects include: diarrhea. Continue reading for a comprehensive list of adverse effects.

Applies to rifapentine: oral tablets.

Side effects include:

Neutropenia, increased AST/ALT, pyuria.

For Healthcare Professionals

Applies to rifapentine: oral tablet.


The most common side effects with the regimen for active pulmonary tuberculosis included anemia, lymphopenia, hemoptysis, neutropenia, cough, thrombocytosis, increased sweating, increased ALT, increased AST, back pain, rash, anorexia, arthralgia, increased blood urea, and headache. The most common side effect with the regimen for latent tuberculosis infection was hypersensitivity reaction.[Ref]


Frequency not reported: Tachycardia, palpitation, orthostatic hypotension, pericarditis, hematoma, thrombosis, flushing, hypotension[Ref]


Common (1% to 10%): Increased sweating/hyperhidrosis, rash, pruritus/itching, maculopapular rash

Uncommon (0.1% to 1%): Skin reaction

Frequency not reported: Purpura, urticaria, skin discoloration, angioedema

Postmarketing reports: Severe cutaneous adverse reactions (e.g., Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms [DRESS] syndrome)[Ref]


Common (1% to 10%): Nausea, dyspepsia, vomiting, diarrhea, abdominal pain

Frequency not reported: Clostridioides difficile-associated diarrhea, gastritis, esophagitis, pancreatitis, salivary gland enlargement, constipation, dry mouth, esophageal irritation[Ref]


Frequency not reported: Hematuria, vaginitis, vaginal hemorrhage, leukorrhea, vulvovaginal candidiasis, vulvovaginal pruritus[Ref]


Very common (10% or more): Anemia (up to 11.4%), lymphopenia (up to 10.5%)

Common (1% to 10%): Neutropenia, thrombocytosis, leukocytosis, thrombocytopenia, lymphadenopathy

Frequency not reported: Leukopenia, lymphocytosis[Ref]


Common (1% to 10%): Increased ALT, increased AST, hepatotoxicity

Uncommon (0.1% to 1%): Hepatitis

Frequency not reported: Bilirubinemia, hepatomegaly, jaundice[Ref]


Common (1% to 10%): Hypersensitivity/hypersensitivity reaction (including hypotension, urticaria, angioedema, acute bronchospasm, conjunctivitis; OR weakness, fatigue, nausea, vomiting, headache, fever, aches, sweats, dizziness, shortness of breath, flushing, chills)

Frequency not reported: Anaphylaxis[Ref]


Common (1% to 10%): Anorexia

Frequency not reported: Hyperglycemia, hyperuricemia, gout, hyperkalemia, decreased appetite, hyperlipidemia[Ref]


Common (1% to 10%): Back pain, arthralgia

Frequency not reported: Arthritis, myalgia/muscle pain, myositis, rhabdomyolysis[Ref]

Nervous system

Common (1% to 10%): Headache, dizziness

Frequency not reported: Somnolence, convulsion, paresthesia, peripheral neuropathy, syncope[Ref]


Common (1% to 10%): Conjunctivitis[Ref]


Common (1% to 10%): Fever/pyrexia

Frequency not reported: Increased alkaline phosphatase, asthenia, facial edema, fungal infection, abortion, death, fatigue, chest pain, chills, feeling jittery, viral infection, aches, body fluid discoloration, weakness, influenza-like syndrome


Frequency not reported: Anxiety, confusion, depression, disorientation, suicidal ideation[Ref]


Common (1% to 10%): Increased blood urea

Frequency not reported: Azotemia[Ref]


Common (1% to 10%): Hemoptysis, coughing/cough

Frequency not reported: Dysphonia, dyspnea/shortness of breath, pneumonitis, pulmonary fibrosis, asthma, bronchospasm, laryngeal edema, laryngitis, pharyngitis, oropharyngeal pain, bronchial hyperactivity, epistaxis, acute bronchospasm[Ref]


1. "Product Information. Priftin (rifapentine)." sanofi-aventis (2020):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.